Life Technologies to Collaborate with Merck Serono for Companion Diagnostics Development and Commercialization

 Life Technologies to Collaborate with Merck Serono for Companion Diagnostics
                      Development and Commercialization

- Increasing focus on targeted therapeutics indicates market growth for
companion diagnostics

- Long-term collaboration aimed at developing, obtaining regulatory approval
and commercializing companion diagnostics for selected Merck Serono drug
development programs

- Life Technologies uniquely positioned to provide pharma with flexible, cost
effective options for CDx development

PR Newswire

CARLSBAD, Calif., July 16, 2013

CARLSBAD, Calif., July 16, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ:LIFE - News) today announced that the company has signed an agreement
to collaborate with Merck Serono, a division of Merck KGaA, Darmstadt,
Germany, for current and future companion diagnostics projects. The current
agreement constitutes the first collaboration between the two companies and
represents another step in Life Technologies' strategy to develop its
diagnostic business through internal development, collaborations and select
acquisitions.

The non-exclusive agreement covers an initial project for oncology and
provides for a long-term collaboration across a potentially broad range of
Life instrument platforms and a wide range of therapeutic areas. Financial
terms of the agreement were not disclosed.

"Life Technologies' combination of platforms and capabilities are unique in
the companion diagnostics space, particularly in oncology," said Ronnie
Andrews, President, Genetic & Medical Sciences at Life Technologies. "With our
recent acquisition of Compendia Bioscience, we possess bioinformatics
solutions and cancer biomarker expertise to collaborate with pharma on each
phase of the drug development process, from biomarker hypothesis to assay
development concurrently with drugs to approved diagnostic tests."

"By helping pharma target the right cancer patients in clinical trials," said
Andrews, "we believe that we have the potential to rapidly accelerate cancer
drug development and this is good for everyone – for Life Technologies and our
pharma partners, and most importantly, for patients."

The collaboration will seek to combine the biomarkers identified by Merck's
translational research with Life Technologies' proprietary platform
technologies and to develop companion diagnostics concurrently with Merck's
drug development programs. The collaboration will also work to simultaneously
seek regulatory approval of Merck's drug and Life Technologies' companion
diagnostic. Life Technologies offers a variety of platform technologies that
support the development of new diagnostics. These technologies span both
genetic and proteomic analysis, including next-generation sequencing, Sanger
sequencing, qPCR and flow cytometry, some of which have already received
clearance by the Food and Drug Administration (FDA). If successful, the
agreement will be followed by a commercialization agreement under which Life
Technologies will commercialize the companion diagnostic in agreed upon
territories.

"Life Technologies is uniquely positioned to provide pharma a flexible, cost
effective means to manage the evolution of the of companion diagnostic assays
through the drug development process," said Andrews.

According to FDA, a companion diagnostic is an in vitro diagnostic device that
provides information that is essential for the safe and effective use of a
corresponding therapy. In 2011, the FDA released draft guidance addressing the
use of companion diagnostics in clinical development and the review and
approval process for diagnostics and associated new therapies.^1 In addition
the European Medicines Agency (EMA) has recently announced it is updating the
guideline on evaluation of anticancer medicines to include companion
diagnostics.^2

References
1. Draft Guidance for Industry and Food and Drug Administration Staff - In
Vitro Companion Diagnostic Devices, Issued July 14, 2011. Available from:
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm262292.htm,
accessed 15 March 2013
2. European Medicines Agency updates guideline on evaluation of anticancer
medicines, 11 January 2013. Available from:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/12/news_detail_001679.jsp&mid=WC0b01ac058004d5c1,
accessed 15 March 2013

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by Life Technologies with the Securities and Exchange
Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Suzanne Clancy
760-602-4545
858-205-4235 (mobile)
suzanne.clancy@lifetech.com

SOURCE Life Technologies Corporation

Website: http://www.lifetech.com